A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder

Human Psychopharmacology

Volumn 24, Issue 2, 2009, Pages 145-152

  Schieber, Frank C ^a   Boulton, David W ^a   Balch, Alfred H ^a   Croop, Robert ^a   Mallikaarjun, Suresh ^b   Benson, Jeannine ^a   Carlson, Berit X ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aripiprazole; Atypical antipsychotic; Bipolar I disorder; Lamotrigine; Pharmacokinetics

Indexed keywords

ARIPIPRAZOLE; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; GABAPENTIN; LAMOTRIGINE; LITHIUM SALT; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; TRIAZINE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSTONIA; ECG ABNORMALITY; FEMALE; HUMAN; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; OPEN STUDY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESTLESSNESS; STEADY STATE; STEVENS JOHNSON SYNDROME; TIME TO MAXIMUM PLASMA CONCENTRATION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG INTERACTION; MIDDLE AGED;

ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TRIAZINES;

EID: 63849316361     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.999     Document Type: Article

References (37)

1. Abilify. 2007. Bristol-Myers Squibb/Otsuka America Pharmaceutical Inc, Aripiprazole (Abilify) Prescribing Information. Bristol-Myers Squibb & Otsuka America Pharmaceutical, Inc: Princeton, NJ.
2. Allison DB, Casey DE. 2001. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62 (Suppl 7): 22-31.
3. APA. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. Guilford Press: New York.
4. APA. 2002. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159 (Suppl 4): 1-50.
5. Boulton D, Vanderslice T, Kornhauser D, Geraldes M, Kolia G, Vaccharajani N. 2004. Effects of aripiprazole on the steady-statepharmacokinetics of valporic acid. Eur Neuropsychopharmacol 14 (Supp 3): 291.
6. Bowden CL. 2004. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 65 (Suppl 15): 21-24.
7. Bowden C, Calabrese J, Sachs G, et al. 2003. A. placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients With bipolar I disorder. Arch Gen Psychiatry 60(4): 392-400.
8. Calabrese JR, Bowden CL, Sachs G, et al. 2003. A. placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64(9): 1013-1024.
9. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. 2005. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 45(1): 89-93.
10. DeLeon A, Patel NC, Crismon ML, 2004. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26(5): 649-666.
11. Dillenschneider A, Sanchez R, McQuade RD, Torbeyns A. 2007. Aripiprazole monotherapy in acute bipolar I mania: a randomized, placebo- & haloperidol-controlled study (CN138-162). Eur Arch Psychiatry Clin Neurosci 257 (Suppl. 2): 35.
12. Elwes RD, Binnie CD. 1996. Clinical pharmacokinetics of newer anti-epileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet 30(6): 403-415.
13. Glassman AH, Bigger JT, Jr 2001. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158(11): 1774-1782.
14. Goodwin GM. 2003. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17(2): 149-173; discussion 147.
15. Green MD, Bishop WP, Tephly TR. 1995. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos 23(3): 299-302.
16. Jann MW, Hon YY, Shamsi SA, Zheng J, Awad EA, Spratlin V. 2006. Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy 26(5): 627-633.
17. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. 2002. The antipsychotic aripiprazole, is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 441(3): 137-140.
18. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. 2004. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483(1): 45-53.
19. Keck PE, Jr, Calabrese JR, McIntyre RS, et a l. 2007. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68(10): 1480-1491.
20. Keck PE, Calabrese JR, McQuade RD, et al. 2006. A Randomized, double-blind, placebo-controlled 26-Week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67(4): 626-637.
21. Keck PE, Jr, Marcus R, Tourkodimitris S, et al. 2003. A. placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160(9): 1651-1658.
22. Keck PE, Jr, Mendlwicz J, Calabrese JR, et al. 2000. A review of randomized, controlled clinical trials in acute mania. J Affect Disord 59(Suppl 1): S31-S37.
23. Lamictal. 2007. Prescribing Information. http://us.gsk.com/products/ assets/us_lamictal.pdf.
24. Mallikaarjun S, Salazar DE, Bramer SL. 2004. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 44(2): 179-187.
25. Reimers A, Skogvoll E, Sund JK, Spigset O. 2005. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol 25(4): 342-348.
26. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. 1999. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 353(9171): 2190-2194.
27. Sachs G, Sanchez R, Marcus R, et al. 2006. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 20(4): 536-546.
28. Saha A, Ali MW, Ingenito G, Wilber R, Luo X, Bramer S. 2002. Safety and tolerability of aripiprazole at doses higher than 30 mg. Int J Neuropsychopharmacol 5(Suppl 1): S185, abstract p. 184.E.026.
29. Schlienger RG, Shapiro LE, Shear NH. 1998. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 39(Suppl 7): S22-S26.
30. Shapiro DA, Renock S, Arrington E, et al. 2003. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8): 1400-1411.
31. Swainston Harrison T, Perry CM. 2004. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64(15): 1715-1736.
32. Tohen M, Zhang F, Taylor CC, et al. 2001. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 65(1): 85-93.
33. Turrone P, Kapur S, Seeman MV, Flint AJ. 2002. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159(1): 133-135.
34. Vieta E, Boutin M, Sanchez R, et al., on behalf of the Aripiprazole Study Group. 2005. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 187(9): 235-242.
35. Vieta E, Loze JY, T'Joen C, McQuade RD, Marcus RN, Sanchez R. 2007. Adjunctive aripiprazole in bipolar mania partially non-responsive to valproate/lithium: a placebo-controlled study (CN138-134). Eur Arch Psychiatry Clin Neurosci 257(Suppl 2): 36.
36. Yalcin B, Karaduman A. 2000. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. J Am Acad Dermatol 43(5 Pt 2): 898-899.
37. Zimbroff DL, Marcus RN, Manos G, et al. 2007. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 27(2): 171-176.